Provided by Tiger Trade Technology Pte. Ltd.

MediciNova

1.36
+0.06004.62%
Post-market: 1.360.00000.00%16:10 EST
Volume:40.17K
Turnover:53.39K
Market Cap:66.84M
PE:-5.55
High:1.40
Open:1.33
Low:1.30
Close:1.30
52wk High:1.96
52wk Low:1.13
Shares:49.15M
Float Shares:42.08M
Volume Ratio:0.44
T/O Rate:0.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2449
EPS(LYR):-0.2445
ROE:-25.50%
ROA:-16.36%
PB:1.61
PE(LYR):-5.56

Loading ...

Press Release: MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

Dow Jones
·
Nov 18, 2025

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

GlobeNewswire
·
Nov 07, 2025

MediciNova Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Nov 04, 2025

BRIEF-MediciNova Completes Patient Enrollment In MN-001 Trial For Tipelukast In MN-001-NATG-202 Study

Reuters
·
Nov 04, 2025

MediciNova Completes Enrollment in Phase 2 Trial of Tipelukast for NAFLD and Hypertriglyceridemia

Reuters
·
Nov 04, 2025

Medicinova Announces Completion of Patient Enrollment in Mn-001-Natg-202 Clinical Trial of Mn-001 (Tipelukast)

THOMSON REUTERS
·
Nov 04, 2025

MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

GlobeNewswire
·
Nov 04, 2025

MediciNova Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Oct 31, 2025

Why Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading?

Benzinga_recent_news
·
Oct 31, 2025

MediciNova compounds demonstrate novel therapeutic approach for Atherosclerosis

TIPRANKS
·
Oct 31, 2025

MediciNova Reports Positive Results for Tipelukast in Cholesterol Metabolism Study

Reuters
·
Oct 31, 2025

MediciNova Inc. to Present Corporate Overview at LD Micro Main Event XIX Investor Conference

Reuters
·
Oct 06, 2025

MediciNova Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Sep 22, 2025

MediciNova Completes Patient Enrollment for Phase 2b/3 ALS Trial of MN-166

Reuters
·
Sep 22, 2025

Medicinova Announces Completion of Patient Enrollment in Combat-ALS Phase 2B/3 Clinical Trial of Mn-166 (Ibudilast)

THOMSON REUTERS
·
Sep 22, 2025

Medicinova Announces Poster Presentation of Combat-ALS Clinical Trial at the 36TH International Symposium on ALS/Mnd

THOMSON REUTERS
·
Sep 16, 2025

MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND

GlobeNewswire
·
Sep 16, 2025

BRIEF-MediciNova Provides Shareholder Update on Key Developments

Reuters
·
Sep 08, 2025

MediciNova Achieves Target Enrollment for COMBAT-ALS Trial, Advances Development of MN-166 for ALS Treatment

Reuters
·
Sep 08, 2025

Medicinova Provides Shareholder Update on Key Developments

THOMSON REUTERS
·
Sep 08, 2025